

PRODUCT INFORMATION



PRI-724

Item No. 41728

CAS Registry No.: 1422253-38-0

Formal Name: (6S,9S,9aS)-hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-8-(8-quinolinylmethyl)-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide

MF: C₃₃H₃₅N₆O₇P


FW: 658.7

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PRI-724 is supplied as a solid. A stock solution may be made by dissolving the PRI-724 in the solvent of choice, which should be purged with an inert gas. PRI-724 is soluble (≥10 mg/ml) in DMSO.

Description

PRI-724 is a prodrug form of the β -catenin/CREB-binding protein (CBP) inhibitor C-82 and a derivative of ICG-001 (Item No. 16257).¹ It is cytotoxic to GES-1 gastric mucosal and HGC-27, MKN45, and AGS gastric cancer cells (IC₅₀s = 16.53, 9.8, 44.28, and 3.48 μ M, respectively) and enhances decreases in viability induced by lonidamine (Item No. 14640) or 2-deoxy-D-glucose (2-DG; Item No. 14325) in CAL 27, SCC-25, and BICR 22 tongue squamous carcinoma cells.^{2,3} PRI-724 (0.4 mg/animal) reduces hepatic fibrosis in a mouse model of liver fibrosis induced by carbon tetrachloride (CCl₄).¹ It reduces the proliferation of CD4⁺ or CD8⁺ stem cell memory and central memory T cells in a rhesus macaque model of antiretroviral therapy-suppressed simian immunodeficiency virus (SIV) infection when administered at doses of 10 or 20 mg/kg per day.⁴

References

1. Osawa, Y., Oboki, K., Imamura, J., *et al.* Inhibition of cyclic adenosine monophosphate (cAMP)-response element-binding protein (CREB)-binding protein (CBP)/ β -catenin reduces liver fibrosis in mice. *EBioMedicine* **2**(11), 1751-1758 (2105).
2. Yu, Z., Jiang, X., Qin, L., *et al.* A novel UBE2T inhibitor suppresses Wnt/ β -catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. *Oncogene* **40**(5), 1027-1042 (2021).
3. Kleszcz, R. and Paluszczak, J. The Wnt signaling pathway inhibitors improve the therapeutic activity of glycolysis modulators against tongue cancer cells. *Int. J. Mol. Sci.* **23**(3), 1248 (2022).
4. Mavigner, M., Zaroni, M., Tharp, G.K., *et al.* Pharmacological modulation of the Wnt/ β -catenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4⁺ T cells in antiretroviral therapy-suppressed simian immunodeficiency virus-infected macaques. *J. Virol.* **94**(1), e01094-19 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM